Product Description: YM022 is a highly potent, selective and orally active gastrin/cholecystokinin (CCK)-B receptor (CCK-BR) antagonist. YM022 shows the Ki values of 68 pM and 63 nM for CCK-B and CCK-A receptor, respectively[1]. YM022 can inhibit gastrin-induced gastric acid secretion and histidine decarboxylase activation in vivo[3].
Applications: Metabolism-protein/nucleotide metabolism
Formula: C32H28N4O3
References: [1]Nishida A, et al. Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo.J Pharmacol Exp Ther. 1994 May;269(2):725-31./[2]Kitano M, et al. Long-lasting cholecystokinin(2) receptor blockade after a single subcutaneous injection of YF476 or YM022.Br J Pharmacol. 2000 Jun;130(3):699-705./[3]Beinborn M, et al. Small synthetic ligands of the cholecystokinin-B/gastrin receptor can mimic the function of endogenous peptide hormones.Yale J Biol Med. 1998 May-Aug;71(3-4):337-46.
CAS Number: 145084-28-2
Molecular Weight: 516.59
Compound Purity: 99.93
Research Area: Metabolic Disease
Target: CCR
Deutsch
English
